'We report on the protocolized use of tecovirimat (SIGA Technologies), an antiviral drug with activity against orthopoxviruses (including monkeypox and smallpox),1 under an expanded access program for all patients with monkeypox virus (MPXV) disease in Mbaïki, Central African Republic, between December 2021 and February 2022.2 Included in the study were 14 patients in whom MPXV infection had been diagnosed.'

#monkeypox #tecovirimat #nejm

https://www.nejm.org/doi/full/10.1056/NEJMc2210015?query=featured_home